Zivo Bioscience director buys 1,766 shares

Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock.

(Moderate)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.

Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.

Insider Trade Summary

Net Buyer: 1,766 shares

Net Buy 1 txn

Insider Maggiore Christopher D.

Role Director, 10% Owner

Bought 1,766 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,766	$8.49	$15K

Holdings After Transaction: Common Stock — 519,292 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zivo Bioscience (ZIVO) disclose for Christopher D. Maggiore?

Zivo Bioscience disclosed that director and 10% owner Christopher D. Maggiore purchased 1,766 shares of common stock. The transaction occurred on January 14, 2026, and was reported as an open-market purchase at $8.49 per share under transaction code "P."

At what price did Christopher D. Maggiore buy Zivo Bioscience (ZIVO) shares?

Christopher D. Maggiore purchased Zivo Bioscience common stock at $8.49 per share. The Form 4 shows a single transaction code "P" for 1,766 shares on January 14, 2026, reflecting an open-market or private purchase at that stated price.

How many Zivo Bioscience (ZIVO) shares does Christopher D. Maggiore own after this transaction?

After the reported transaction, Christopher D. Maggiore beneficially owns 519,292 shares of Zivo Bioscience common stock. The filing shows these shares as directly owned, reflecting his status as both a company director and a more than 10% beneficial owner.

What does transaction code "P" mean in the Zivo Bioscience (ZIVO) Form 4 filing?

Transaction code "P" in the Zivo Bioscience Form 4 indicates a purchase of securities. In this case, it identifies Maggiore’s acquisition of 1,766 shares of common stock on January 14, 2026, at a price of $8.49 per share in an open-market or similar transaction.

Is the Zivo Bioscience (ZIVO) Form 4 filing for direct or indirect ownership?

The Zivo Bioscience Form 4 filing shows Maggiore’s ownership as direct, labeled with "D" in the ownership column. No nature-of-ownership footnote is provided, indicating the 519,292 shares are reported as directly held by the reporting person after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/27/2026 - 05:09 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maggiore Christopher D.

(Last)

(First)

(Middle)

2125 BUTTERFIELD ROAD

SUITE 100

(Street)

TROY

48084

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/14/2026		P		1,766	A	$8.49	519,292	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Christopher D. Maggiore	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR